AptarGroup, Inc. (NYSE: ATR) Stock Competitors & Peer Comparison
See ATR's competitors and their performance on the NYSE and across the wider stock market.
Peer Comparison Table: Medical - Instruments & Supplies Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for ATR and its NYSE peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| ATR | $142.50 | -1.07% | 9B | 24.92 | $5.72 | +1.36% |
| ISRG | $452.80 | -3.36% | 160B | 47.07 | $9.62 | N/A |
| BDX | $211.88 | -0.78% | 57.7B | 16.30 | $13.00 | +1.88% |
| BDXA | $59.24 | -2.24% | 55.9B | 45.70 | $1.30 | +1.88% |
| MDLN | $39.64 | -0.30% | 34.8B | 29.06 | $1.36 | N/A |
| RMD | $235.30 | -1.68% | 33.1B | 20.40 | $11.53 | +1.06% |
| WST | $399.81 | +1.87% | 27.9B | 43.48 | $9.20 | +0.22% |
| HOLX | $76.01 | +0.00% | 17B | 31.54 | $2.41 | N/A |
| SOLV | $90.38 | +3.67% | 15.4B | 12.73 | $7.10 | N/A |
| BDXB | $48.16 | +1.39% | 13.7B | 7.60 | $6.33 | +1.88% |
Stock Comparison
Intuitive Surgical, Inc. (NASDAQ: ISRG)
ATR vs ISRG Comparison November 2026
AptarGroup, Inc. (NYSE: ATR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATR stands at 9B. In comparison, ISRG has a market cap of 160B. Regarding current trading prices, ATR is priced at $142.50 on the NYSE, while ISRG trades at $452.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATR currently has a P/E ratio of 24.92, whereas ISRG's P/E ratio is 47.07. In terms of profitability, ATR's ROE is +0.10%, compared to ISRG's ROE of +0.17%. Regarding short-term risk, ATR is less volatile compared to ISRG. This indicates lower risk in terms of short-term price fluctuations for ATR.Check ISRG's competition here
Becton, Dickinson and Company (NYSE: BDX)
ATR vs BDX Comparison November 2026
AptarGroup, Inc. (NYSE: ATR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATR stands at 9B. In comparison, BDX has a market cap of 57.7B. Regarding current trading prices, ATR is priced at $142.50 on the NYSE, while BDX trades at $211.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATR currently has a P/E ratio of 24.92, whereas BDX's P/E ratio is 16.30. In terms of profitability, ATR's ROE is +0.10%, compared to BDX's ROE of +0.04%. Regarding short-term risk, ATR is less volatile compared to BDX. This indicates lower risk in terms of short-term price fluctuations for ATR.Check BDX's competition here
Becton, Dickinson and Company (NYSE: BDXA)
ATR vs BDXA Comparison November 2026
AptarGroup, Inc. (NYSE: ATR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATR stands at 9B. In comparison, BDXA has a market cap of 55.9B. Regarding current trading prices, ATR is priced at $142.50 on the NYSE, while BDXA trades at $59.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATR currently has a P/E ratio of 24.92, whereas BDXA's P/E ratio is 45.70. In terms of profitability, ATR's ROE is +0.10%, compared to BDXA's ROE of +0.04%. Regarding short-term risk, ATR is less volatile compared to BDXA. This indicates lower risk in terms of short-term price fluctuations for ATR.Check BDXA's competition here
Medline Inc. (NASDAQ: MDLN)
ATR vs MDLN Comparison November 2026
AptarGroup, Inc. (NYSE: ATR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATR stands at 9B. In comparison, MDLN has a market cap of 34.8B. Regarding current trading prices, ATR is priced at $142.50 on the NYSE, while MDLN trades at $39.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATR currently has a P/E ratio of 24.92, whereas MDLN's P/E ratio is 29.06. In terms of profitability, ATR's ROE is +0.10%, compared to MDLN's ROE of +0.05%. Regarding short-term risk, ATR is less volatile compared to MDLN. This indicates lower risk in terms of short-term price fluctuations for ATR.Check MDLN's competition here
ResMed Inc. (NYSE: RMD)
ATR vs RMD Comparison November 2026
AptarGroup, Inc. (NYSE: ATR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATR stands at 9B. In comparison, RMD has a market cap of 33.1B. Regarding current trading prices, ATR is priced at $142.50 on the NYSE, while RMD trades at $235.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATR currently has a P/E ratio of 24.92, whereas RMD's P/E ratio is 20.40. In terms of profitability, ATR's ROE is +0.10%, compared to RMD's ROE of +0.25%. Regarding short-term risk, ATR is more volatile compared to RMD. This indicates higher risk in terms of short-term price fluctuations for ATR.Check RMD's competition here
West Pharmaceutical Services, Inc. (NYSE: WST)
ATR vs WST Comparison November 2026
AptarGroup, Inc. (NYSE: ATR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATR stands at 9B. In comparison, WST has a market cap of 27.9B. Regarding current trading prices, ATR is priced at $142.50 on the NYSE, while WST trades at $399.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATR currently has a P/E ratio of 24.92, whereas WST's P/E ratio is 43.48. In terms of profitability, ATR's ROE is +0.10%, compared to WST's ROE of +0.21%. Regarding short-term risk, ATR is less volatile compared to WST. This indicates lower risk in terms of short-term price fluctuations for ATR.Check WST's competition here
Hologic, Inc. (NASDAQ: HOLX)
ATR vs HOLX Comparison November 2026
AptarGroup, Inc. (NYSE: ATR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATR stands at 9B. In comparison, HOLX has a market cap of 17B. Regarding current trading prices, ATR is priced at $142.50 on the NYSE, while HOLX trades at $76.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATR currently has a P/E ratio of 24.92, whereas HOLX's P/E ratio is 31.54. In terms of profitability, ATR's ROE is +0.10%, compared to HOLX's ROE of +0.11%. Regarding short-term risk, ATR is more volatile compared to HOLX. This indicates higher risk in terms of short-term price fluctuations for ATR.Check HOLX's competition here
Solventum Corporation (NYSE: SOLV)
ATR vs SOLV Comparison November 2026
AptarGroup, Inc. (NYSE: ATR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATR stands at 9B. In comparison, SOLV has a market cap of 15.4B. Regarding current trading prices, ATR is priced at $142.50 on the NYSE, while SOLV trades at $90.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATR currently has a P/E ratio of 24.92, whereas SOLV's P/E ratio is 12.73. In terms of profitability, ATR's ROE is +0.10%, compared to SOLV's ROE of +0.03%. Regarding short-term risk, ATR is less volatile compared to SOLV. This indicates lower risk in terms of short-term price fluctuations for ATR.Check SOLV's competition here
Becton, Dickinson and Company (NYSE: BDXB)
ATR vs BDXB Comparison November 2026
AptarGroup, Inc. (NYSE: ATR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATR stands at 9B. In comparison, BDXB has a market cap of 13.7B. Regarding current trading prices, ATR is priced at $142.50 on the NYSE, while BDXB trades at $48.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATR currently has a P/E ratio of 24.92, whereas BDXB's P/E ratio is 7.60. In terms of profitability, ATR's ROE is +0.10%, compared to BDXB's ROE of +0.04%. Regarding short-term risk, ATR is less volatile compared to BDXB. This indicates lower risk in terms of short-term price fluctuations for ATR.Check BDXB's competition here
Baxter International Inc. (NYSE: BAX)
ATR vs BAX Comparison November 2026
AptarGroup, Inc. (NYSE: ATR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATR stands at 9B. In comparison, BAX has a market cap of 13.3B. Regarding current trading prices, ATR is priced at $142.50 on the NYSE, while BAX trades at $25.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATR currently has a P/E ratio of 24.92, whereas BAX's P/E ratio is 12.39. In terms of profitability, ATR's ROE is +0.10%, compared to BAX's ROE of -0.12%. Regarding short-term risk, ATR is less volatile compared to BAX. This indicates lower risk in terms of short-term price fluctuations for ATR.Check BAX's competition here
The Cooper Companies, Inc. (NASDAQ: COO)
ATR vs COO Comparison November 2026
AptarGroup, Inc. (NYSE: ATR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATR stands at 9B. In comparison, COO has a market cap of 11.9B. Regarding current trading prices, ATR is priced at $142.50 on the NYSE, while COO trades at $62.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATR currently has a P/E ratio of 24.92, whereas COO's P/E ratio is 13.67. In terms of profitability, ATR's ROE is +0.10%, compared to COO's ROE of +0.07%. Regarding short-term risk, ATR is more volatile compared to COO. This indicates higher risk in terms of short-term price fluctuations for ATR.Check COO's competition here
Repligen Corporation (NASDAQ: RGEN)
ATR vs RGEN Comparison November 2026
AptarGroup, Inc. (NYSE: ATR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATR stands at 9B. In comparison, RGEN has a market cap of 11.1B. Regarding current trading prices, ATR is priced at $142.50 on the NYSE, while RGEN trades at $173.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATR currently has a P/E ratio of 24.92, whereas RGEN's P/E ratio is 96.38. In terms of profitability, ATR's ROE is +0.10%, compared to RGEN's ROE of -0.01%. Regarding short-term risk, ATR is less volatile compared to RGEN. This indicates lower risk in terms of short-term price fluctuations for ATR.Check RGEN's competition here
Avantor, Inc. (NYSE: AVTR)
ATR vs AVTR Comparison November 2026
AptarGroup, Inc. (NYSE: ATR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATR stands at 9B. In comparison, AVTR has a market cap of 10.5B. Regarding current trading prices, ATR is priced at $142.50 on the NYSE, while AVTR trades at $15.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATR currently has a P/E ratio of 24.92, whereas AVTR's P/E ratio is 18.19. In terms of profitability, ATR's ROE is +0.10%, compared to AVTR's ROE of +0.06%. Regarding short-term risk, ATR is less volatile compared to AVTR. This indicates lower risk in terms of short-term price fluctuations for ATR.Check AVTR's competition here
Bausch + Lomb Corporation (NYSE: BLCO)
ATR vs BLCO Comparison November 2026
AptarGroup, Inc. (NYSE: ATR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATR stands at 9B. In comparison, BLCO has a market cap of 7.1B. Regarding current trading prices, ATR is priced at $142.50 on the NYSE, while BLCO trades at $19.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATR currently has a P/E ratio of 24.92, whereas BLCO's P/E ratio is 30.72. In terms of profitability, ATR's ROE is +0.10%, compared to BLCO's ROE of -0.02%. Regarding short-term risk, ATR is less volatile compared to BLCO. This indicates lower risk in terms of short-term price fluctuations for ATR.Check BLCO's competition here
Teleflex Incorporated (NYSE: TFX)
ATR vs TFX Comparison November 2026
AptarGroup, Inc. (NYSE: ATR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATR stands at 9B. In comparison, TFX has a market cap of 6.4B. Regarding current trading prices, ATR is priced at $142.50 on the NYSE, while TFX trades at $150.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATR currently has a P/E ratio of 24.92, whereas TFX's P/E ratio is 17.22. In terms of profitability, ATR's ROE is +0.10%, compared to TFX's ROE of +0.10%. Regarding short-term risk, ATR is less volatile compared to TFX. This indicates lower risk in terms of short-term price fluctuations for ATR.Check TFX's competition here
Merit Medical Systems, Inc. (NASDAQ: MMSI)
ATR vs MMSI Comparison November 2026
AptarGroup, Inc. (NYSE: ATR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATR stands at 9B. In comparison, MMSI has a market cap of 5.2B. Regarding current trading prices, ATR is priced at $142.50 on the NYSE, while MMSI trades at $87.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATR currently has a P/E ratio of 24.92, whereas MMSI's P/E ratio is 22.30. In terms of profitability, ATR's ROE is +0.10%, compared to MMSI's ROE of +0.10%. Regarding short-term risk, ATR is more volatile compared to MMSI. This indicates higher risk in terms of short-term price fluctuations for ATR.Check MMSI's competition here
ICU Medical, Inc. (NASDAQ: ICUI)
ATR vs ICUI Comparison November 2026
AptarGroup, Inc. (NYSE: ATR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATR stands at 9B. In comparison, ICUI has a market cap of 4.3B. Regarding current trading prices, ATR is priced at $142.50 on the NYSE, while ICUI trades at $172.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATR currently has a P/E ratio of 24.92, whereas ICUI's P/E ratio is 21.53. In terms of profitability, ATR's ROE is +0.10%, compared to ICUI's ROE of +0.03%. Regarding short-term risk, ATR is less volatile compared to ICUI. This indicates lower risk in terms of short-term price fluctuations for ATR.Check ICUI's competition here
Envista Holdings Corp (NYSE: NVST)
ATR vs NVST Comparison November 2026
AptarGroup, Inc. (NYSE: ATR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATR stands at 9B. In comparison, NVST has a market cap of 4B. Regarding current trading prices, ATR is priced at $142.50 on the NYSE, while NVST trades at $25.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATR currently has a P/E ratio of 24.92, whereas NVST's P/E ratio is 17.13. In terms of profitability, ATR's ROE is +0.10%, compared to NVST's ROE of +0.21%. Regarding short-term risk, ATR is less volatile compared to NVST. This indicates lower risk in terms of short-term price fluctuations for ATR.Check NVST's competition here
Pulse Biosciences, Inc. (NASDAQ: PLSE)
ATR vs PLSE Comparison November 2026
AptarGroup, Inc. (NYSE: ATR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATR stands at 9B. In comparison, PLSE has a market cap of 3.8B. Regarding current trading prices, ATR is priced at $142.50 on the NYSE, while PLSE trades at $53.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATR currently has a P/E ratio of 24.92, whereas PLSE's P/E ratio is -45.08. In terms of profitability, ATR's ROE is +0.10%, compared to PLSE's ROE of -0.78%. Regarding short-term risk, ATR is less volatile compared to PLSE. This indicates lower risk in terms of short-term price fluctuations for ATR.Check PLSE's competition here
Stevanato Group S.p.A. (NYSE: STVN)
ATR vs STVN Comparison November 2026
AptarGroup, Inc. (NYSE: ATR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATR stands at 9B. In comparison, STVN has a market cap of 3.7B. Regarding current trading prices, ATR is priced at $142.50 on the NYSE, while STVN trades at $13.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATR currently has a P/E ratio of 24.92, whereas STVN's P/E ratio is 20.50. In terms of profitability, ATR's ROE is +0.10%, compared to STVN's ROE of +0.09%. Regarding short-term risk, ATR is less volatile compared to STVN. This indicates lower risk in terms of short-term price fluctuations for ATR.Check STVN's competition here
AtriCure, Inc. (NASDAQ: ATRC)
ATR vs ATRC Comparison November 2026
AptarGroup, Inc. (NYSE: ATR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATR stands at 9B. In comparison, ATRC has a market cap of 3B. Regarding current trading prices, ATR is priced at $142.50 on the NYSE, while ATRC trades at $58.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATR currently has a P/E ratio of 24.92, whereas ATRC's P/E ratio is 1817.08. In terms of profitability, ATR's ROE is +0.10%, compared to ATRC's ROE of +0.03%. Regarding short-term risk, ATR is less volatile compared to ATRC. This indicates lower risk in terms of short-term price fluctuations for ATR.Check ATRC's competition here
BioLife Solutions, Inc. (NASDAQ: BLFS)
ATR vs BLFS Comparison November 2026
AptarGroup, Inc. (NYSE: ATR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATR stands at 9B. In comparison, BLFS has a market cap of 1.9B. Regarding current trading prices, ATR is priced at $142.50 on the NYSE, while BLFS trades at $38.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATR currently has a P/E ratio of 24.92, whereas BLFS's P/E ratio is 37.49. In terms of profitability, ATR's ROE is +0.10%, compared to BLFS's ROE of +0.13%. Regarding short-term risk, ATR is less volatile compared to BLFS. This indicates lower risk in terms of short-term price fluctuations for ATR.Check BLFS's competition here
DENTSPLY SIRONA Inc. (NASDAQ: XRAY)
ATR vs XRAY Comparison November 2026
AptarGroup, Inc. (NYSE: ATR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATR stands at 9B. In comparison, XRAY has a market cap of 1.9B. Regarding current trading prices, ATR is priced at $142.50 on the NYSE, while XRAY trades at $9.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATR currently has a P/E ratio of 24.92, whereas XRAY's P/E ratio is 6.62. In terms of profitability, ATR's ROE is +0.10%, compared to XRAY's ROE of -0.09%. Regarding short-term risk, ATR is less volatile compared to XRAY. This indicates lower risk in terms of short-term price fluctuations for ATR.Check XRAY's competition here
LeMaitre Vascular, Inc. (NASDAQ: LMAT)
ATR vs LMAT Comparison November 2026
AptarGroup, Inc. (NYSE: ATR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATR stands at 9B. In comparison, LMAT has a market cap of 1.9B. Regarding current trading prices, ATR is priced at $142.50 on the NYSE, while LMAT trades at $80.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATR currently has a P/E ratio of 24.92, whereas LMAT's P/E ratio is 29.76. In terms of profitability, ATR's ROE is +0.10%, compared to LMAT's ROE of +0.15%. Regarding short-term risk, ATR is less volatile compared to LMAT. This indicates lower risk in terms of short-term price fluctuations for ATR.Check LMAT's competition here
Azenta, Inc. (NASDAQ: AZTA)
ATR vs AZTA Comparison November 2026
AptarGroup, Inc. (NYSE: ATR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATR stands at 9B. In comparison, AZTA has a market cap of 1.7B. Regarding current trading prices, ATR is priced at $142.50 on the NYSE, while AZTA trades at $39.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATR currently has a P/E ratio of 24.92, whereas AZTA's P/E ratio is 93.33. In terms of profitability, ATR's ROE is +0.10%, compared to AZTA's ROE of -0.08%. Regarding short-term risk, ATR is less volatile compared to AZTA. This indicates lower risk in terms of short-term price fluctuations for ATR.Check AZTA's competition here
Kestra Medical Technologies, Ltd. (NASDAQ: KMTS)
ATR vs KMTS Comparison November 2026
AptarGroup, Inc. (NYSE: ATR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATR stands at 9B. In comparison, KMTS has a market cap of 1.7B. Regarding current trading prices, ATR is priced at $142.50 on the NYSE, while KMTS trades at $28.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATR currently has a P/E ratio of 24.92, whereas KMTS's P/E ratio is -10.86. In terms of profitability, ATR's ROE is +0.10%, compared to KMTS's ROE of -0.64%. Regarding short-term risk, ATR is less volatile compared to KMTS. This indicates lower risk in terms of short-term price fluctuations for ATR.Check KMTS's competition here
STAAR Surgical Company (NASDAQ: STAA)
ATR vs STAA Comparison November 2026
AptarGroup, Inc. (NYSE: ATR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATR stands at 9B. In comparison, STAA has a market cap of 1.3B. Regarding current trading prices, ATR is priced at $142.50 on the NYSE, while STAA trades at $25.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATR currently has a P/E ratio of 24.92, whereas STAA's P/E ratio is 44.23. In terms of profitability, ATR's ROE is +0.10%, compared to STAA's ROE of +0.00%. Regarding short-term risk, ATR is less volatile compared to STAA. This indicates lower risk in terms of short-term price fluctuations for ATR.Check STAA's competition here
Atrion Corporation (NASDAQ: ATRI)
ATR vs ATRI Comparison November 2026
AptarGroup, Inc. (NYSE: ATR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATR stands at 9B. In comparison, ATRI has a market cap of 809.4M. Regarding current trading prices, ATR is priced at $142.50 on the NYSE, while ATRI trades at $459.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATR currently has a P/E ratio of 24.92, whereas ATRI's P/E ratio is 64.50. In terms of profitability, ATR's ROE is +0.10%, compared to ATRI's ROE of +0.08%. Regarding short-term risk, ATR is more volatile compared to ATRI. This indicates higher risk in terms of short-term price fluctuations for ATR.Check ATRI's competition here
MiniMed Group, Inc. (NASDAQ: MMEDV)
ATR vs MMEDV Comparison November 2026
AptarGroup, Inc. (NYSE: ATR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATR stands at 9B. In comparison, MMEDV has a market cap of 495.6M. Regarding current trading prices, ATR is priced at $142.50 on the NYSE, while MMEDV trades at $17.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATR currently has a P/E ratio of 24.92, whereas MMEDV's P/E ratio is N/A. In terms of profitability, ATR's ROE is +0.10%, compared to MMEDV's ROE of N/A. Regarding short-term risk, ATR is less volatile compared to MMEDV. This indicates lower risk in terms of short-term price fluctuations for ATR.Check MMEDV's competition here
AngioDynamics, Inc. (NASDAQ: ANGO)
ATR vs ANGO Comparison November 2026
AptarGroup, Inc. (NYSE: ATR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATR stands at 9B. In comparison, ANGO has a market cap of 493.1M. Regarding current trading prices, ATR is priced at $142.50 on the NYSE, while ANGO trades at $11.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATR currently has a P/E ratio of 24.92, whereas ANGO's P/E ratio is -30.06. In terms of profitability, ATR's ROE is +0.10%, compared to ANGO's ROE of -0.19%. Regarding short-term risk, ATR is less volatile compared to ANGO. This indicates lower risk in terms of short-term price fluctuations for ATR.Check ANGO's competition here
Embecta Corp. (NASDAQ: EMBC)
ATR vs EMBC Comparison November 2026
AptarGroup, Inc. (NYSE: ATR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATR stands at 9B. In comparison, EMBC has a market cap of 350M. Regarding current trading prices, ATR is priced at $142.50 on the NYSE, while EMBC trades at $6.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATR currently has a P/E ratio of 24.92, whereas EMBC's P/E ratio is 2.38. In terms of profitability, ATR's ROE is +0.10%, compared to EMBC's ROE of -0.14%. Regarding short-term risk, ATR is less volatile compared to EMBC. This indicates lower risk in terms of short-term price fluctuations for ATR.Check EMBC's competition here
Sanara MedTech Inc. (NASDAQ: SMTI)
ATR vs SMTI Comparison November 2026
AptarGroup, Inc. (NYSE: ATR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATR stands at 9B. In comparison, SMTI has a market cap of 289.9M. Regarding current trading prices, ATR is priced at $142.50 on the NYSE, while SMTI trades at $31.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATR currently has a P/E ratio of 24.92, whereas SMTI's P/E ratio is -525.83. In terms of profitability, ATR's ROE is +0.10%, compared to SMTI's ROE of -4.74%. Regarding short-term risk, ATR is less volatile compared to SMTI. This indicates lower risk in terms of short-term price fluctuations for ATR.Check SMTI's competition here
OraSure Technologies, Inc. (NASDAQ: OSUR)
ATR vs OSUR Comparison November 2026
AptarGroup, Inc. (NYSE: ATR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATR stands at 9B. In comparison, OSUR has a market cap of 237.9M. Regarding current trading prices, ATR is priced at $142.50 on the NYSE, while OSUR trades at $3.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATR currently has a P/E ratio of 24.92, whereas OSUR's P/E ratio is -5.00. In terms of profitability, ATR's ROE is +0.10%, compared to OSUR's ROE of -0.15%. Regarding short-term risk, ATR is less volatile compared to OSUR. This indicates lower risk in terms of short-term price fluctuations for ATR.Check OSUR's competition here
Utah Medical Products, Inc. (NASDAQ: UTMD)
ATR vs UTMD Comparison November 2026
AptarGroup, Inc. (NYSE: ATR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATR stands at 9B. In comparison, UTMD has a market cap of 230.4M. Regarding current trading prices, ATR is priced at $142.50 on the NYSE, while UTMD trades at $72.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATR currently has a P/E ratio of 24.92, whereas UTMD's P/E ratio is 21.48. In terms of profitability, ATR's ROE is +0.10%, compared to UTMD's ROE of +0.09%. Regarding short-term risk, ATR is less volatile compared to UTMD. This indicates lower risk in terms of short-term price fluctuations for ATR.Check UTMD's competition here
Pro-Dex, Inc. (NASDAQ: PDEX)
ATR vs PDEX Comparison November 2026
AptarGroup, Inc. (NYSE: ATR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATR stands at 9B. In comparison, PDEX has a market cap of 201M. Regarding current trading prices, ATR is priced at $142.50 on the NYSE, while PDEX trades at $63.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATR currently has a P/E ratio of 24.92, whereas PDEX's P/E ratio is 17.21. In terms of profitability, ATR's ROE is +0.10%, compared to PDEX's ROE of +0.26%. Regarding short-term risk, ATR is less volatile compared to PDEX. This indicates lower risk in terms of short-term price fluctuations for ATR.Check PDEX's competition here
Anbio Biotechnology Class A Ordinary Shares (NASDAQ: NNNN)
ATR vs NNNN Comparison November 2026
AptarGroup, Inc. (NYSE: ATR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATR stands at 9B. In comparison, NNNN has a market cap of 169M. Regarding current trading prices, ATR is priced at $142.50 on the NYSE, while NNNN trades at $3.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATR currently has a P/E ratio of 24.92, whereas NNNN's P/E ratio is 25.67. In terms of profitability, ATR's ROE is +0.10%, compared to NNNN's ROE of +0.27%. Regarding short-term risk, ATR is less volatile compared to NNNN. This indicates lower risk in terms of short-term price fluctuations for ATR.Check NNNN's competition here
KORU Medical Systems, Inc. (NASDAQ: KRMD)
ATR vs KRMD Comparison November 2026
AptarGroup, Inc. (NYSE: ATR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATR stands at 9B. In comparison, KRMD has a market cap of 141.7M. Regarding current trading prices, ATR is priced at $142.50 on the NYSE, while KRMD trades at $3.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATR currently has a P/E ratio of 24.92, whereas KRMD's P/E ratio is -77.12. In terms of profitability, ATR's ROE is +0.10%, compared to KRMD's ROE of -0.11%. Regarding short-term risk, ATR is less volatile compared to KRMD. This indicates lower risk in terms of short-term price fluctuations for ATR.Check KRMD's competition here
Stereotaxis, Inc. (AMEX: STXS)
ATR vs STXS Comparison November 2026
AptarGroup, Inc. (NYSE: ATR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATR stands at 9B. In comparison, STXS has a market cap of 111.2M. Regarding current trading prices, ATR is priced at $142.50 on the NYSE, while STXS trades at $1.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATR currently has a P/E ratio of 24.92, whereas STXS's P/E ratio is -6.53. In terms of profitability, ATR's ROE is +0.10%, compared to STXS's ROE of -1.33%. Regarding short-term risk, ATR is less volatile compared to STXS. This indicates lower risk in terms of short-term price fluctuations for ATR.Check STXS's competition here
Akoya Biosciences, Inc. (NASDAQ: AKYA)
ATR vs AKYA Comparison November 2026
AptarGroup, Inc. (NYSE: ATR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATR stands at 9B. In comparison, AKYA has a market cap of 64.4M. Regarding current trading prices, ATR is priced at $142.50 on the NYSE, while AKYA trades at $1.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATR currently has a P/E ratio of 24.92, whereas AKYA's P/E ratio is -1.34. In terms of profitability, ATR's ROE is +0.10%, compared to AKYA's ROE of -1.80%. Regarding short-term risk, ATR is more volatile compared to AKYA. This indicates higher risk in terms of short-term price fluctuations for ATR.Check AKYA's competition here
Precision Optics Corporation, Inc. (NASDAQ: POCI)
ATR vs POCI Comparison November 2026
AptarGroup, Inc. (NYSE: ATR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATR stands at 9B. In comparison, POCI has a market cap of 53.8M. Regarding current trading prices, ATR is priced at $142.50 on the NYSE, while POCI trades at $4.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATR currently has a P/E ratio of 24.92, whereas POCI's P/E ratio is -10.66. In terms of profitability, ATR's ROE is +0.10%, compared to POCI's ROE of -0.24%. Regarding short-term risk, ATR is more volatile compared to POCI. This indicates higher risk in terms of short-term price fluctuations for ATR.Check POCI's competition here
SkyAI, Inc. (NASDAQ: STSS)
ATR vs STSS Comparison November 2026
AptarGroup, Inc. (NYSE: ATR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATR stands at 9B. In comparison, STSS has a market cap of 53.7M. Regarding current trading prices, ATR is priced at $142.50 on the NYSE, while STSS trades at $1.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATR currently has a P/E ratio of 24.92, whereas STSS's P/E ratio is -0.02. In terms of profitability, ATR's ROE is +0.10%, compared to STSS's ROE of -1.54%. Regarding short-term risk, ATR is less volatile compared to STSS. This indicates lower risk in terms of short-term price fluctuations for ATR.Check STSS's competition here
Singular Genomics Systems, Inc. (NASDAQ: OMIC)
ATR vs OMIC Comparison November 2026
AptarGroup, Inc. (NYSE: ATR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATR stands at 9B. In comparison, OMIC has a market cap of 50.8M. Regarding current trading prices, ATR is priced at $142.50 on the NYSE, while OMIC trades at $20.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATR currently has a P/E ratio of 24.92, whereas OMIC's P/E ratio is -0.58. In terms of profitability, ATR's ROE is +0.10%, compared to OMIC's ROE of -0.43%. Regarding short-term risk, ATR is more volatile compared to OMIC. This indicates higher risk in terms of short-term price fluctuations for ATR.Check OMIC's competition here
GlucoTrack, Inc. (NASDAQ: IGAP)
ATR vs IGAP Comparison November 2026
AptarGroup, Inc. (NYSE: ATR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATR stands at 9B. In comparison, IGAP has a market cap of 50.2M. Regarding current trading prices, ATR is priced at $142.50 on the NYSE, while IGAP trades at $3.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATR currently has a P/E ratio of 24.92, whereas IGAP's P/E ratio is -10.52. In terms of profitability, ATR's ROE is +0.10%, compared to IGAP's ROE of +1.80%. Regarding short-term risk, ATR is more volatile compared to IGAP. This indicates higher risk in terms of short-term price fluctuations for ATR.Check IGAP's competition here
Daxor Corporation (NASDAQ: DXR)
ATR vs DXR Comparison November 2026
AptarGroup, Inc. (NYSE: ATR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATR stands at 9B. In comparison, DXR has a market cap of 49.4M. Regarding current trading prices, ATR is priced at $142.50 on the NYSE, while DXR trades at $8.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATR currently has a P/E ratio of 24.92, whereas DXR's P/E ratio is 6.88. In terms of profitability, ATR's ROE is +0.10%, compared to DXR's ROE of +0.13%. Regarding short-term risk, ATR is less volatile compared to DXR. This indicates lower risk in terms of short-term price fluctuations for ATR.Check DXR's competition here
Harvard Bioscience, Inc. (NASDAQ: HBIO)
ATR vs HBIO Comparison November 2026
AptarGroup, Inc. (NYSE: ATR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATR stands at 9B. In comparison, HBIO has a market cap of 38.2M. Regarding current trading prices, ATR is priced at $142.50 on the NYSE, while HBIO trades at $8.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATR currently has a P/E ratio of 24.92, whereas HBIO's P/E ratio is -23.31. In terms of profitability, ATR's ROE is +0.10%, compared to HBIO's ROE of -0.92%. Regarding short-term risk, ATR is less volatile compared to HBIO. This indicates lower risk in terms of short-term price fluctuations for ATR.Check HBIO's competition here
Nephros, Inc. (NASDAQ: NEPH)
ATR vs NEPH Comparison November 2026
AptarGroup, Inc. (NYSE: ATR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATR stands at 9B. In comparison, NEPH has a market cap of 30.6M. Regarding current trading prices, ATR is priced at $142.50 on the NYSE, while NEPH trades at $2.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATR currently has a P/E ratio of 24.92, whereas NEPH's P/E ratio is 46.92. In terms of profitability, ATR's ROE is +0.10%, compared to NEPH's ROE of +0.17%. Regarding short-term risk, ATR is less volatile compared to NEPH. This indicates lower risk in terms of short-term price fluctuations for ATR.Check NEPH's competition here
SmileDirectClub, Inc. (NASDAQ: SDC)
ATR vs SDC Comparison November 2026
AptarGroup, Inc. (NYSE: ATR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATR stands at 9B. In comparison, SDC has a market cap of 29.1M. Regarding current trading prices, ATR is priced at $142.50 on the NYSE, while SDC trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATR currently has a P/E ratio of 24.92, whereas SDC's P/E ratio is -0.03. In terms of profitability, ATR's ROE is +0.10%, compared to SDC's ROE of -1.96%. Regarding short-term risk, ATR is less volatile compared to SDC. This indicates lower risk in terms of short-term price fluctuations for ATR.Check SDC's competition here
Milestone Scientific Inc. (AMEX: MLSS)
ATR vs MLSS Comparison November 2026
AptarGroup, Inc. (NYSE: ATR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATR stands at 9B. In comparison, MLSS has a market cap of 27.5M. Regarding current trading prices, ATR is priced at $142.50 on the NYSE, while MLSS trades at $0.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATR currently has a P/E ratio of 24.92, whereas MLSS's P/E ratio is -6.07. In terms of profitability, ATR's ROE is +0.10%, compared to MLSS's ROE of -1.49%. Regarding short-term risk, ATR is less volatile compared to MLSS. This indicates lower risk in terms of short-term price fluctuations for ATR.Check MLSS's competition here
Jin Medical International Ltd. (NASDAQ: ZJYL)
ATR vs ZJYL Comparison November 2026
AptarGroup, Inc. (NYSE: ATR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATR stands at 9B. In comparison, ZJYL has a market cap of 26.1M. Regarding current trading prices, ATR is priced at $142.50 on the NYSE, while ZJYL trades at $3.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATR currently has a P/E ratio of 24.92, whereas ZJYL's P/E ratio is 22.78. In terms of profitability, ATR's ROE is +0.10%, compared to ZJYL's ROE of +0.04%. Regarding short-term risk, ATR is less volatile compared to ZJYL. This indicates lower risk in terms of short-term price fluctuations for ATR.Check ZJYL's competition here
Invacare Corporation (NYSE: IVC)
ATR vs IVC Comparison November 2026
AptarGroup, Inc. (NYSE: ATR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATR stands at 9B. In comparison, IVC has a market cap of 24.9M. Regarding current trading prices, ATR is priced at $142.50 on the NYSE, while IVC trades at $0.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATR currently has a P/E ratio of 24.92, whereas IVC's P/E ratio is -0.79. In terms of profitability, ATR's ROE is +0.10%, compared to IVC's ROE of -0.46%. Regarding short-term risk, ATR is less volatile compared to IVC. This indicates lower risk in terms of short-term price fluctuations for ATR.Check IVC's competition here
Retractable Technologies, Inc. (AMEX: RVP)
ATR vs RVP Comparison November 2026
AptarGroup, Inc. (NYSE: ATR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATR stands at 9B. In comparison, RVP has a market cap of 16.9M. Regarding current trading prices, ATR is priced at $142.50 on the NYSE, while RVP trades at $0.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATR currently has a P/E ratio of 24.92, whereas RVP's P/E ratio is -4.69. In terms of profitability, ATR's ROE is +0.10%, compared to RVP's ROE of -0.05%. Regarding short-term risk, ATR is less volatile compared to RVP. This indicates lower risk in terms of short-term price fluctuations for ATR.Check RVP's competition here
Bionano Genomics, Inc. (NASDAQ: BNGO)
ATR vs BNGO Comparison November 2026
AptarGroup, Inc. (NYSE: ATR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATR stands at 9B. In comparison, BNGO has a market cap of 13.5M. Regarding current trading prices, ATR is priced at $142.50 on the NYSE, while BNGO trades at $1.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATR currently has a P/E ratio of 24.92, whereas BNGO's P/E ratio is -0.38. In terms of profitability, ATR's ROE is +0.10%, compared to BNGO's ROE of -0.79%. Regarding short-term risk, ATR is less volatile compared to BNGO. This indicates lower risk in terms of short-term price fluctuations for ATR.Check BNGO's competition here
Femasys Inc. (NASDAQ: FEMY)
ATR vs FEMY Comparison November 2026
AptarGroup, Inc. (NYSE: ATR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATR stands at 9B. In comparison, FEMY has a market cap of 11.6M. Regarding current trading prices, ATR is priced at $142.50 on the NYSE, while FEMY trades at $1.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATR currently has a P/E ratio of 24.92, whereas FEMY's P/E ratio is -0.31. In terms of profitability, ATR's ROE is +0.10%, compared to FEMY's ROE of -2.26%. Regarding short-term risk, ATR is less volatile compared to FEMY. This indicates lower risk in terms of short-term price fluctuations for ATR.Check FEMY's competition here
Regentis Biomaterials Ltd. (AMEX: RGNT)
ATR vs RGNT Comparison November 2026
AptarGroup, Inc. (NYSE: ATR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATR stands at 9B. In comparison, RGNT has a market cap of 8.1M. Regarding current trading prices, ATR is priced at $142.50 on the NYSE, while RGNT trades at $1.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATR currently has a P/E ratio of 24.92, whereas RGNT's P/E ratio is -0.47. In terms of profitability, ATR's ROE is +0.10%, compared to RGNT's ROE of N/A. Regarding short-term risk, ATR is less volatile compared to RGNT. This indicates lower risk in terms of short-term price fluctuations for ATR.Check RGNT's competition here
Lucyd, Inc (NASDAQ: LUCY)
ATR vs LUCY Comparison November 2026
AptarGroup, Inc. (NYSE: ATR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATR stands at 9B. In comparison, LUCY has a market cap of 7.2M. Regarding current trading prices, ATR is priced at $142.50 on the NYSE, while LUCY trades at $0.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATR currently has a P/E ratio of 24.92, whereas LUCY's P/E ratio is -0.64. In terms of profitability, ATR's ROE is +0.10%, compared to LUCY's ROE of -0.89%. Regarding short-term risk, ATR is less volatile compared to LUCY. This indicates lower risk in terms of short-term price fluctuations for ATR.Check LUCY's competition here
NanoString Technologies, Inc. (NASDAQ: NSTG)
ATR vs NSTG Comparison November 2026
AptarGroup, Inc. (NYSE: ATR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATR stands at 9B. In comparison, NSTG has a market cap of 5.1M. Regarding current trading prices, ATR is priced at $142.50 on the NYSE, while NSTG trades at $0.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATR currently has a P/E ratio of 24.92, whereas NSTG's P/E ratio is -0.03. In terms of profitability, ATR's ROE is +0.10%, compared to NSTG's ROE of -1.43%. Regarding short-term risk, ATR is less volatile compared to NSTG. This indicates lower risk in terms of short-term price fluctuations for ATR.Check NSTG's competition here
Cuprina Holdings (Cayman) Limited Class A Ordinary Shares (NASDAQ: CUPR)
ATR vs CUPR Comparison November 2026
AptarGroup, Inc. (NYSE: ATR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATR stands at 9B. In comparison, CUPR has a market cap of 4.8M. Regarding current trading prices, ATR is priced at $142.50 on the NYSE, while CUPR trades at $1.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATR currently has a P/E ratio of 24.92, whereas CUPR's P/E ratio is -1.31. In terms of profitability, ATR's ROE is +0.10%, compared to CUPR's ROE of -0.85%. Regarding short-term risk, ATR is less volatile compared to CUPR. This indicates lower risk in terms of short-term price fluctuations for ATR.Check CUPR's competition here
Predictive Oncology Inc. (NASDAQ: POAI)
ATR vs POAI Comparison November 2026
AptarGroup, Inc. (NYSE: ATR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATR stands at 9B. In comparison, POAI has a market cap of 3.6M. Regarding current trading prices, ATR is priced at $142.50 on the NYSE, while POAI trades at $4.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATR currently has a P/E ratio of 24.92, whereas POAI's P/E ratio is -0.38. In terms of profitability, ATR's ROE is +0.10%, compared to POAI's ROE of -21.19%. Regarding short-term risk, ATR is less volatile compared to POAI. This indicates lower risk in terms of short-term price fluctuations for ATR.Check POAI's competition here
Meihua International Medical Technologies Co., Ltd. (NASDAQ: MHUA)
ATR vs MHUA Comparison November 2026
AptarGroup, Inc. (NYSE: ATR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATR stands at 9B. In comparison, MHUA has a market cap of 2.4M. Regarding current trading prices, ATR is priced at $142.50 on the NYSE, while MHUA trades at $7.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATR currently has a P/E ratio of 24.92, whereas MHUA's P/E ratio is 0.25. In terms of profitability, ATR's ROE is +0.10%, compared to MHUA's ROE of +0.07%. Regarding short-term risk, ATR is more volatile compared to MHUA. This indicates higher risk in terms of short-term price fluctuations for ATR.Check MHUA's competition here
G Medical Innovations Holdings Ltd (NASDAQ: GMVD)
ATR vs GMVD Comparison November 2026
AptarGroup, Inc. (NYSE: ATR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATR stands at 9B. In comparison, GMVD has a market cap of 1.8M. Regarding current trading prices, ATR is priced at $142.50 on the NYSE, while GMVD trades at $0.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATR currently has a P/E ratio of 24.92, whereas GMVD's P/E ratio is -0.01. In terms of profitability, ATR's ROE is +0.10%, compared to GMVD's ROE of +2.09%. Regarding short-term risk, ATR is less volatile compared to GMVD. This indicates lower risk in terms of short-term price fluctuations for ATR.Check GMVD's competition here
G Medical Innovations Holdings Ltd (NASDAQ: GMVDW)
ATR vs GMVDW Comparison November 2026
AptarGroup, Inc. (NYSE: ATR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATR stands at 9B. In comparison, GMVDW has a market cap of 1.8M. Regarding current trading prices, ATR is priced at $142.50 on the NYSE, while GMVDW trades at $7.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATR currently has a P/E ratio of 24.92, whereas GMVDW's P/E ratio is N/A. In terms of profitability, ATR's ROE is +0.10%, compared to GMVDW's ROE of +3.68%. Regarding short-term risk, ATR is less volatile compared to GMVDW. This indicates lower risk in terms of short-term price fluctuations for ATR.Check GMVDW's competition here
NEXGEL, Inc. (NASDAQ: NXGL)
ATR vs NXGL Comparison November 2026
AptarGroup, Inc. (NYSE: ATR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATR stands at 9B. In comparison, NXGL has a market cap of 1.7M. Regarding current trading prices, ATR is priced at $142.50 on the NYSE, while NXGL trades at $3.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATR currently has a P/E ratio of 24.92, whereas NXGL's P/E ratio is -5.01. In terms of profitability, ATR's ROE is +0.10%, compared to NXGL's ROE of -1.33%. Regarding short-term risk, ATR is less volatile compared to NXGL. This indicates lower risk in terms of short-term price fluctuations for ATR.Check NXGL's competition here
Avinger, Inc. (NASDAQ: AVGR)
ATR vs AVGR Comparison November 2026
AptarGroup, Inc. (NYSE: ATR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATR stands at 9B. In comparison, AVGR has a market cap of 1.5M. Regarding current trading prices, ATR is priced at $142.50 on the NYSE, while AVGR trades at $0.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATR currently has a P/E ratio of 24.92, whereas AVGR's P/E ratio is -0.05. In terms of profitability, ATR's ROE is +0.10%, compared to AVGR's ROE of +17.82%. Regarding short-term risk, ATR is less volatile compared to AVGR. This indicates lower risk in terms of short-term price fluctuations for ATR.Check AVGR's competition here
NEXGEL, Inc. (NASDAQ: NXGLW)
ATR vs NXGLW Comparison November 2026
AptarGroup, Inc. (NYSE: ATR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATR stands at 9B. In comparison, NXGLW has a market cap of 496.3K. Regarding current trading prices, ATR is priced at $142.50 on the NYSE, while NXGLW trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATR currently has a P/E ratio of 24.92, whereas NXGLW's P/E ratio is -0.01. In terms of profitability, ATR's ROE is +0.10%, compared to NXGLW's ROE of -1.33%. Regarding short-term risk, ATR is less volatile compared to NXGLW. This indicates lower risk in terms of short-term price fluctuations for ATR.Check NXGLW's competition here
Lucyd, Inc (NASDAQ: LUCYW)
ATR vs LUCYW Comparison November 2026
AptarGroup, Inc. (NYSE: ATR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATR stands at 9B. In comparison, LUCYW has a market cap of 296.1K. Regarding current trading prices, ATR is priced at $142.50 on the NYSE, while LUCYW trades at $0.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATR currently has a P/E ratio of 24.92, whereas LUCYW's P/E ratio is N/A. In terms of profitability, ATR's ROE is +0.10%, compared to LUCYW's ROE of -0.89%. Regarding short-term risk, ATR is less volatile compared to LUCYW. This indicates lower risk in terms of short-term price fluctuations for ATR.Check LUCYW's competition here
Hill-Rom Holdings, Inc. (NYSE: HRC)
ATR vs HRC Comparison November 2026
AptarGroup, Inc. (NYSE: ATR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATR stands at 9B. In comparison, HRC has a market cap of 0. Regarding current trading prices, ATR is priced at $142.50 on the NYSE, while HRC trades at $155.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATR currently has a P/E ratio of 24.92, whereas HRC's P/E ratio is 41.92. In terms of profitability, ATR's ROE is +0.10%, compared to HRC's ROE of +0.14%. Regarding short-term risk, ATR is more volatile compared to HRC. This indicates higher risk in terms of short-term price fluctuations for ATR.Check HRC's competition here
Analogic Corporation (NASDAQ: ALOG)
ATR vs ALOG Comparison November 2026
AptarGroup, Inc. (NYSE: ATR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATR stands at 9B. In comparison, ALOG has a market cap of 0. Regarding current trading prices, ATR is priced at $142.50 on the NYSE, while ALOG trades at $83.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATR currently has a P/E ratio of 24.92, whereas ALOG's P/E ratio is 40.93. In terms of profitability, ATR's ROE is +0.10%, compared to ALOG's ROE of -0.15%. Regarding short-term risk, ATR is more volatile compared to ALOG. This indicates higher risk in terms of short-term price fluctuations for ATR.Check ALOG's competition here
Antares Pharma, Inc. (NASDAQ: ATRS)
ATR vs ATRS Comparison November 2026
AptarGroup, Inc. (NYSE: ATR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATR stands at 9B. In comparison, ATRS has a market cap of 0. Regarding current trading prices, ATR is priced at $142.50 on the NYSE, while ATRS trades at $5.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATR currently has a P/E ratio of 24.92, whereas ATRS's P/E ratio is 14.95. In terms of profitability, ATR's ROE is +0.10%, compared to ATRS's ROE of +0.31%. Regarding short-term risk, ATR is more volatile compared to ATRS. This indicates higher risk in terms of short-term price fluctuations for ATR.Check ATRS's competition here
IntriCon Corporation (NASDAQ: IIN)
ATR vs IIN Comparison November 2026
AptarGroup, Inc. (NYSE: ATR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATR stands at 9B. In comparison, IIN has a market cap of 0. Regarding current trading prices, ATR is priced at $142.50 on the NYSE, while IIN trades at $24.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATR currently has a P/E ratio of 24.92, whereas IIN's P/E ratio is 226.45. In terms of profitability, ATR's ROE is +0.10%, compared to IIN's ROE of -0.00%. Regarding short-term risk, ATR is more volatile compared to IIN. This indicates higher risk in terms of short-term price fluctuations for ATR.Check IIN's competition here
Apria, Inc. (NASDAQ: APR)
ATR vs APR Comparison November 2026
AptarGroup, Inc. (NYSE: ATR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATR stands at 9B. In comparison, APR has a market cap of 0. Regarding current trading prices, ATR is priced at $142.50 on the NYSE, while APR trades at $37.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATR currently has a P/E ratio of 24.92, whereas APR's P/E ratio is 22.59. In terms of profitability, ATR's ROE is +0.10%, compared to APR's ROE of +9.81%. Regarding short-term risk, ATR is more volatile compared to APR. This indicates higher risk in terms of short-term price fluctuations for ATR.Check APR's competition here
Invuity, Inc. (NASDAQ: IVTY)
ATR vs IVTY Comparison November 2026
AptarGroup, Inc. (NYSE: ATR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ATR stands at 9B. In comparison, IVTY has a market cap of 0. Regarding current trading prices, ATR is priced at $142.50 on the NYSE, while IVTY trades at $7.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ATR currently has a P/E ratio of 24.92, whereas IVTY's P/E ratio is -3.80. In terms of profitability, ATR's ROE is +0.10%, compared to IVTY's ROE of -2.40%. Regarding short-term risk, ATR is more volatile compared to IVTY. This indicates higher risk in terms of short-term price fluctuations for ATR.Check IVTY's competition here